- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2016–2026 · program · P01
Comprehensive dissection of the CLL genome & phenome to improve patient outcomes
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
Role of SNF5 in regulating SWI/SNF complex assembly & targeting in rhabdoid tumor
Xiaofeng Wang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
A. Thomas Look · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2020 · research · R01
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer
Christopher J Sweeney · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K08
The mechanism of DNA damage and chromothripsis from chromosome segregation errors
Alexander Spektor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
Intratumor heterogeneity and therapeutic resistance
Michalina Janiszewska · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R00
The Role of EglN1 and HIF in Normal Hematopoiesis and in Leukemia
Julie-Aurore Losman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
New Paradigms for Targeting Truncal Driver Mutations
William G. Kaelin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Targeting Immunogenicity to the MPER Hinge and C-helix for BNAb Elicitation
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · cooperative agreement · U01
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection
Brian Matthew Wolpin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R50
Immunogenomic analytical approaches for research and clinical applications
Sachet Ashok Shukla · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
Anthony G Letai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R50
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
Gregory Howard Bird · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
New Paradigms for Targeting Truncal Driver Mutations
William G. Kaelin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
New Paradigms for Targeting Truncal Driver Mutations
William G. Kaelin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Neuroimmune mechanisms of depression in adults with HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Conformational Landscape of the HIV-1 Envelope Glycoproteins
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K08
The mechanism of DNA damage and chromothripsis from chromosome segregation errors
Alexander Spektor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2020 · research · R01
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
Anthony G Letai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K07
Material Hardship as a Targetable Measure of Poverty in Pediatric Cancer
Kira O. Bona · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · cooperative agreement · U01
Circulating Biomarker Consortium for Pancreatic Cancer Early Detection
Brian Matthew Wolpin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · training · T32
Cancer Immunology Training Grant
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
New Paradigms for Targeting Truncal Driver Mutations
William G. Kaelin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R01
Neuroimmune mechanisms of depression in adults with HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer
A. Thomas Look · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2027 · research · R01
Axonal transport and chemotherapy induced peripheral neuropathy
Rosalind A. Segal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
Chun-Wei David Chen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · grant · PCRP
Identify the Metabolic Dependencies of Obesity-Associated Aggressive Prostate Cancer to Develop Tailored Imaging and Therapeutic Approaches
Giorgia Zadra · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2016–2021 · research · R01
Identifying causal variants and genes underlying breast cancer risk loci
Matthew L Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · research · R50
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
Gregory Howard Bird · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Conformational Landscape of the HIV-1 Envelope Glycoproteins
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · career development · K00
The role of CMTR2 in Lung Cancer
Alena Yermalovich · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
The role of circulating Slit2 in adipose thermogenesis and diabetes
Katrin Jennifer Svensson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · training · T32
Cancer Immunology Training Grant
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · training · T32
Cancer Immunology Training Grant
Kai W Wucherpfennig · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · grant · NFRP
Identification of Highly Active Drug Combinations for the Therapy of NF1-Associated Malignant Peripheral Nerve Sheath Tumors Using the Zebrafish Model
A. Thomas Look · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2016–2021 · research · R01
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
Kenneth C. Anderson · Dana-Farber Cancer Institute · funded by National Institutes of Health
